Last reviewed · How we verify

NCT06981169: PROPULSION

PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults

Recruiting now Last updated 20 May 2025
What this trial tests

trial testing FeNO in Asthma in 1,500 participants. Currently enrolling.

Timeline
24 March 2025
Primary endpoint
1 July 2026
1 July 2027

Quick facts

Lead sponsorUniversité de Sherbrooke
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,500
Start date24 March 2025
Primary completion1 July 2026
Estimated completion1 July 2027
Sites3 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Université de Sherbrooke — full company profile →

Who can join

6 and older, any sex, with Asthma or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this observational study is to assess the relevance of inflammometry (based on the measurement of fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC)) as a tool for prioritizing respiratory diagnostic tests. The study will evaluate the role of inflammometry (FeNO and BEC) in prioritizing diagnostic respiratory tests. It will include patients aged six and older with suspected asthma, referred by non-pulmonologists for diagnostic asthma testing (spirometry or methacholine challenge test) at three hospital centers: Sherbrooke University Hospital Center (CHUS), Sainte-Justine University Hospital Center (CHU Sainte-Justine), and the Montreal Children's Hospital. The hypothesis is that using inflammometry as a prioritization tool would reduce diagnostic delays for high-risk patients with elevated biomarkers. This study could help shorten wait times, relieve congestion in diagnostic testing queues, and improve the diagnostic pathway. Additionally, it would enhance the interpretation of pulmonary function test results by incorporating inflammometry findings, leading to better patient stratification. Patients referred from primary care will undergo pulmonary function testing (spirometry ± methacholine challenge) and, as part of the study: FeNO measurement using a portable device Blood test for eosinophil count Questionnaire on asthma control and quality of life, completed at the visit and at follow-ups at 4, 8, and 12 months

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Integrating blood eosinophils and exhaled nitric oxide (FeNO) in asthma diagnostic pathways for adults and children: the PROPULSION SANTÉ observational study with translational sub-studies (DIVE, DIVE2)-protocols.
    Gronnier M, Désy L, Pouliot L, Lemieux SÈ, et al · · 2025 · PMID 41314665 · DOI 10.1136/bmjresp-2025-003750

Verify or expand the search:

Other trials of FeNO

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Université de Sherbrooke trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06981169.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing